Developing new options for Cystic Fibrosis lung infections

Disrupting the biofilms that protect chronic lung bacterial infections

Cystic Fibrosis affects 1 in 3,500 births with approximately 70,000 patients worldwide and 31,000 in the USA alone.

Patients develop a thick sticky mucus in their lungs, which are susceptible to infection and which over time results in inflammation and lung function decline.

Respirion is developing a novel inhaled treatment for Cystic Fibrosis patients that combines a widely used antibiotic with a biofilm disrupting agent. This treatment has been shown in an initial patient study to significantly improve bacterial clearance and improve lung function.

Latest News

Journal Articles

Journal of Cystic Fibrosis

The Journal of Cystic Fibrosis published an article titled - Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas…
Company News

MEDIA RELEASE | MRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis

The Medical Research Commercialisation Fund’s Biomedical Translation Fund (MRCF BTF) today announced the launch of a new biotech company, Respirion Pharmaceuticals Pty Ltd (Respirion). Respirion…